{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:08:53Z","timestamp":1784714933959,"version":"3.55.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203000"],"award-info":[{"award-number":["82203000"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2021ZD26"],"award-info":[{"award-number":["ZR2021ZD26"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013280","name":"Major Basic Research Project of the Natural Science Foundation of the Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013280","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010029","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","award":["tstp20221158"],"award-info":[{"award-number":["tstp20221158"]}],"id":[{"id":"10.13039\/501100010029","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010029","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","award":["tsqnz20221164"],"award-info":[{"award-number":["tsqnz20221164"]}],"id":[{"id":"10.13039\/501100010029","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010029","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","award":["2026ZD0553200-2026ZD0553203"],"award-info":[{"award-number":["2026ZD0553200-2026ZD0553203"]}],"id":[{"id":"10.13039\/501100010029","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2025M782095"],"award-info":[{"award-number":["2025M782095"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["ZR2022QH300"],"award-info":[{"award-number":["ZR2022QH300"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jconrel.2026.114991","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T15:02:42Z","timestamp":1777993362000},"page":"114991","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Delivery of a ZBP1 agonist enhances radiotherapy-induced antitumour immunity in hepatocellular carcinoma"],"prefix":"10.1016","volume":"395","author":[{"given":"Hui","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Xu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingru","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daolin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengxuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruizhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoru","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.114991_bb0005","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular Carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.114991_bb0010","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.jconrel.2026.114991_bb0015","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ccell.2024.01.007","article-title":"Precision treatment in advanced hepatocellular carcinoma","volume":"42","author":"Yang","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2026.114991_bb0020","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/s41423-025-01308-4","article-title":"Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy","volume":"22","author":"Seyhan","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.jconrel.2026.114991_bb0025","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.114991_bb0030","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.114991_bb0035","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41571-024-00868-0","article-title":"Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma","volume":"21","author":"Llovet","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.114991_bb0040","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.114991_bb0045","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1053\/j.gastro.2017.06.007","article-title":"Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features","volume":"153","author":"Sia","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2026.114991_bb0050","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2026.114991_bb0055","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.jconrel.2026.114991_bb0060","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2026.114991_bb0065","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","article-title":"Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial","volume":"24","author":"Llovet","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2026.114991_bb0070","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2026.114991_bb0075","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","article-title":"Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma","volume":"28","author":"Zhu","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2026.114991_bb0080","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41568-024-00674-x","article-title":"Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity","volume":"24","author":"Meier","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2026.114991_bb0085","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.114991_bb0090","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000337","article-title":"Consensus guidelines for the definition, detection and interpretation of immunogenic cell death","volume":"8","author":"Galluzzi","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jconrel.2026.114991_bb0095","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.jconrel.2026.114991_bb0100","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-022-04753-7","article-title":"ADAR1 masks the cancer immunotherapeutic promise of ZBP1-driven necroptosis","volume":"606","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.114991_bb0105","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cytogfr.2024.03.005","article-title":"Z-DNA binding protein 1 orchestrates innate immunity and inflammatory cell death","volume":"77","author":"Song","year":"2024","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.jconrel.2026.114991_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2024.109938","article-title":"Z-nucleic acid sensor ZBP1 in sterile inflammation","volume":"261","author":"Song","year":"2024","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jconrel.2026.114991_bb0115","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41590-018-0044-z","article-title":"The immunology of hepatocellular carcinoma","volume":"19","author":"Ringelhan","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2026.114991_bb0120","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/1535-7163.MCT-23-0373","article-title":"Roles of cGAS-STING pathway in radiotherapy combined with immunotherapy for hepatocellular carcinoma","volume":"23","author":"Ma","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2026.114991_bb0125","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41571-018-0073-4","article-title":"Molecular therapies and precision medicine for hepatocellular carcinoma","volume":"15","author":"Llovet","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.114991_bb0130","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","article-title":"Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2026.114991_bb0135","first-page":"498","article-title":"Advances in the treatment of hepatocellular carcinoma: an overview of the current and evolving therapeutic landscape for clinicians","volume":"75","author":"Moris","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jconrel.2026.114991_bb0140","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/gutjnl-2021-325918","article-title":"Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification","volume":"72","author":"Montironi","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2026.114991_bb0145","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41568-020-0246-1","article-title":"Inflammatory microenvironment remodelling by tumour cells after radiotherapy","volume":"20","author":"McLaughlin","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2026.114991_bb0150","doi-asserted-by":"crossref","first-page":"1418965","DOI":"10.3389\/fimmu.2024.1418965","article-title":"The current status and future of targeted-immune combination for hepatocellular carcinoma","volume":"15","author":"Hao","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.114991_bb0155","doi-asserted-by":"crossref","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.114991_bb0160","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.114991_bb0165","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.114991_bb0170","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2026.114991_bb0175","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1080\/14728222.2024.2416975","article-title":"Progress and challenges in glypican-3 targeting for hepatocellular carcinoma therapy","volume":"28","author":"Couzinet","year":"2024","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.jconrel.2026.114991_bb0180","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.ijrobp.2003.09.012","article-title":"Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated","volume":"58","author":"Demaria","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.jconrel.2026.114991_bb0185","first-page":"1676","article-title":"Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer","volume":"6","author":"Huang","year":"2025","journal-title":"Nat. Can."},{"key":"10.1016\/j.jconrel.2026.114991_bb0190","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1158\/1078-0432.CCR-21-1258","article-title":"NASH and hepatocellular carcinoma: immunology and immunotherapy","volume":"29","author":"Pinter","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.114991_bb0195","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/gutjnl-2024-333154","article-title":"Hepatic TM6SF2 activates antitumour immunity to suppress metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma and boosts immunotherapy","volume":"74","author":"Zhang","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2026.114991_bb0200","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","article-title":"Molecular and cellular mechanisms of liver fibrosis and its regression","volume":"18","author":"Kisseleva","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2026.114991_bb0205","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2026.114991_bb0210","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41575-023-00807-x","article-title":"Hepatic inflammatory responses in liver fibrosis","volume":"20","author":"Hammerich","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2026.114991_bb0215","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41575-023-00821-z","article-title":"Friend or foe? The elusive role of hepatic stellate cells in liver cancer","volume":"20","author":"Cogliati","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2026.114991_bb0220","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.114991_bb0225","first-page":"665","article-title":"Targeting Glypican-3 for liver Cancer therapy: clinical applications and detection methods","volume":"13","author":"Zhang","year":"2025","journal-title":"J. Clin. Transl. Hepatol."},{"key":"10.1016\/j.jconrel.2026.114991_bb0230","doi-asserted-by":"crossref","first-page":"1489649","DOI":"10.3389\/fimmu.2024.1489649","article-title":"CAR-T cell therapy for hepatocellular carcinoma: current trends and challenges","volume":"15","author":"Zhou","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.114991_bb0235","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.jhep.2022.03.010","article-title":"Metformin treatment rescues CD8(+) T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD","volume":"77","author":"Wabitsch","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2026.114991_bb0240","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/nrgastro.2017.72","article-title":"The gut microbiome and liver cancer: mechanisms and clinical translation","volume":"14","author":"Yu","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2026.114991_bb0245","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/jgh.16872","article-title":"Current landscape of adoptive cell therapy and challenge to develop \u201coff-the-shelf\u201d therapy for hepatocellular carcinoma","volume":"40","author":"Shin","year":"2025","journal-title":"J. Gastroenterol. Hepatol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926003949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926003949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:20:40Z","timestamp":1783084840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926003949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":49,"alternative-id":["S0168365926003949"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114991","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delivery of a ZBP1 agonist enhances radiotherapy-induced antitumour immunity in hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114991","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114991"}}